HIV Infections Clinical Trial
— YouthHealthOfficial title:
Using Mobile Technology to Prevent HIV and Related Youth Health Problems: Sexual Health, Mental Health and Substance Use in Southwest Uganda
| Verified date | May 2024 |
| Source | New York State Psychiatric Institute |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The goal of the project is to find out how the investigators can use mobile phones to prevent HIV and address related health problems such as sexual health and mental health among adolescents. The investigators will evaluate and adapt an existing text-message and interactive voice recognition (IVR) system. IVR is Interactive voice response is a technology that allows humans to interact with a computer-operated phone system through the use of voice and DTMF tones input via a keypad. The system was designed by FHI 360 (note FHI 360 is the name of the non-profit not an acronym). FHI 360 is an international nonprofit working to improve the health and well-being of people in the United States and around the world. FHI 360 staffs more than 4,000 professionals who work in more than 60 countries. Examples of the existing content is available (https://m4rh.fhi360.org/?page_id=191) and we have a letter of support from FHI 360, included in my funded grant proposal, stating we may use and modify this content as needed. As noted below anyone can access this content by dialing #161 when in Uganda. FHI 360 sexual reproductive health information is currently available across Uganda for free and can be accessed in by dialing #161. The proposed research comprises two phases. Phase 1 involves two steps, (A) "theater pretesting" (includes brief interviews) (B) focus groups (or more detailed interviews depending on COVID-19 guidelines and described in detail below) that will involve asking adolescents to discuss new messages that would provide basic information about pre-exposure prophylaxis (PrEP) as well as, a set of questions about mental health, and alcohol use. We will conduct focus groups with these adolescents and elicit responses to improve the acceptability of the messages (described in detail below). We will then modify any content as needed and conduct Phase 2 which involves (A) randomized control trial and (B) qualitative key informant interviews. Adolescents (N=200) will be randomly assigned to either the mobile phone-based intervention or to standard of care. Through this approach we will evaluate our adaptation of FHI 360's existing text message and interactive voice recognition (IVR). The adaptation will include PrEP information as well as specific mental health and hazardous alcohol use screens, promote HIV prevention for all adolescents, and support linkage to behavioral health counselors for symptomatic adolescents.
| Status | Active, not recruiting |
| Enrollment | 200 |
| Est. completion date | June 2025 |
| Est. primary completion date | September 20, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 15 Years to 19 Years |
| Eligibility | Inclusion Criteria: 1. Adolescents (aged 15-19 years): Self-report during enrollment and confirmed by school personnel or local community leader. 2. Residing in the greater Masaka region in southern Uganda: Self-report during enrollment and confirmed by school personnel or local community leader. 3. Own a mobile phone: Self-report during enrollment and confirmed visually by project director or research assistant. 4. People who have the cognitive capacity to consent: A potential participant will be included if the researcher conducting the consent process determines that the potential participant has the cognitive capacity to consent. This will be determined by through the review of the consent forms. 5. For Phase II, did not participate. In Phase I: Review of study records. Exclusion Criteria: 1. People who are not aged 15-19 years: Self-report during enrollment and confirmed by school personnel or local community leader. 2. People who do not reside in the greater Masaka region in southern Uganda: Self-report during enrollment and confirmed by school personnel or local community leader. 3. People who do not own a mobile phone: Self-report during enrollment and confirmed visually by project director or research assistant. 4. People who do not have the cognitive capacity to consent: A potential participant will be excluded if the researcher conducting the consent process determines that the potential participant has a mental deficit or does not have the cognitive capacity to understand the consent process and proposed research. 5. Participants in phase 1 will be excluded from phase 2: Review of study records |
| Country | Name | City | State |
|---|---|---|---|
| United States | New York State Psychiatric Institute | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| New York State Psychiatric Institute | National Institute of Mental Health (NIMH), Washington University School of Medicine |
United States,
Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995 Jul;56(4):423-32. doi: 10.15288/jsa.1995.56.423. — View Citation
Johnson D, Juras R, Riley P, Chatterji M, Sloane P, Choi SK, Johns B. A randomized controlled trial of the impact of a family planning mHealth service on knowledge and use of contraception. Contraception. 2017 Jan;95(1):90-97. doi: 10.1016/j.contraception.2016.07.009. Epub 2016 Jul 13. — View Citation
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. — View Citation
Olsen PS, Plourde KF, Lasway C, van Praag E. Insights From a Text Messaging-Based Sexual and Reproductive Health Information Program in Tanzania (m4RH): Retrospective Analysis. JMIR Mhealth Uhealth. 2018 Nov 1;6(11):e10190. doi: 10.2196/10190. — View Citation
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. — View Citation
Vahdat HL, L'Engle KL, Plourde KF, Magaria L, Olawo A. There are some questions you may not ask in a clinic: providing contraception information to young people in Kenya using SMS. Int J Gynaecol Obstet. 2013 Nov;123 Suppl 1:e2-6. doi: 10.1016/j.ijgo.2013.07.009. Epub 2013 Aug 2. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | HIV-AIDS Test | Self-report and verified at local clinic number of HIV Tests | 6 month | |
| Secondary | Depression | Pre-Post Scores of Depression as measured by the The Patient Health Questionnaire (PHQ-9). The Patient Health Questionnaire (PHQ-9)(Kroenke K & Spitzer RL, 2001) - a standardized 9-item self-report instrument - was used to assess depression. Participants rate the frequency of their symptoms over the past 2 weeks. Items are rated on a 4-point scale from 0 (not at all) to 3 (nearly every day) and scale scores range from 0 to 27. PHQ-9 scores of 5-9, represent minimal to mild depression, and 10-20 represent moderate to severe depression. As recommended, PHQ-9 scores = 10 were considered indicative of screening positively for clinically significant depressive symptoms (Kroenke K & Spitzer RL, 2001). The PHQ-9 has good test-retest reliability and validity. A score equal to or greater than 10 has a sensitivity of 88% and a specificity of 88% for major depression (Kroenke K & Spitzer RL, 2001). | 6 month | |
| Secondary | Alcohol Use | Pre-Post Alcohol use scores Alcohol Consumption Questions (AUDIT or AUDIT-C). The AUDIT-C (Bohn et al., 1995) is a 3-item screener excerpted from the full standardized 10-item AUDIT tool to assess hazardous alcohol consumption. Items are scored on a 5-point scale for a possible score of 0 to 12. The higher the score, the higher the risk of hazardous alcohol consumption. An AUDIT-C score of 4 or greater in men, and 3 or greater in women is considered positive for hazardous alcohol consumption (Bohn et al., 1995) | 6 month | |
| Secondary | PrEP Use | Pre-Post PrEP Use based on self-report. | 6 month | |
| Secondary | Anxiety | Pre-Post Scores of The Generalized Anxiety Disorder Questionnaire (GAD-7). The GAD-7 is a standardized instrument that asks participants to rate their symptoms over the past two weeks on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). Overall scores for the GAD-7 range from 0 to 21. At a cut-point of 10 (indicative of clinically significant symptoms), the sensitivity and specificity of the scale equals 89% and 82% respectively. The GAD-7 has a Cronbach's alpha of .92, indicating good internal consistency with an intra-class correlation of .83, indicating good procedural validity (Spitzer et al., 2006). | 6 month | |
| Secondary | Mental Health Counseling | Mental Health Counseling sessions self-reported. | 6 month |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |